Results 1 to 10 of about 175,167 (244)
CHAtRF Modulates Cardiac Hypertrophy via SRSF5-Dependent Regulation of Psmg4 Alternative Splicing [PDF]
ResearchtRNA-derived small RNAs (tsRNAs) or tRNA-derived fragments (tRFs) are an important class of regulatory molecules whose role in cardiac hypertrophy remains largely unknown.
Lu-Yu Zhou +12 more
doaj +2 more sources
MiR-26a-5p inhibits GSK3β expression and promotes cardiac hypertrophy in vitro [PDF]
PeerJ, 2020 Background The role of miR-26a-5p expression in cardiac hypertrophy remains unclear. Herein, the effect of miR-26a-5p on cardiac hypertrophy was investigated using phenylephrine (PE)-induced cardiac hypertrophy in vitro and in a rat model of hypertension-
Liqun Tang +3 more
doaj +2 more sources
Cardiac hypertrophy at autopsy [PDF]
Virchows Archiv, 2021 AbstractSince cardiac hypertrophy may be considered a cause of death at autopsy, its assessment requires a uniform approach. Common terminology and methodology to measure the heart weight, size, and thickness as well as a systematic use of cut off values for normality by age, gender, and body weight and height are needed.
Basso C. +9 more
openaire +8 more sources
Multi-Omics Characterization of a Human Stem Cell-Based Model of Cardiac Hypertrophy
Life, 2022 Cardiac hypertrophy is an important and independent risk factor for the development of cardiac myopathy that may lead to heart failure. The mechanisms underlying the development of cardiac hypertrophy are yet not well understood.
Markus Johansson +6 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Pathological cardiac hypertrophy is an important risk factor for cardiovascular disease. However, drug therapies that can reverse the maladaptive process and restore heart function are limited. Ganoderma lucidum polysaccharides (GLPs) are one of the main
Changlin Zhen +19 more
doaj +1 more source
Speckle Tracking Based Strain Analysis Is Sensitive for Early Detection of Pathological Cardiac Hypertrophy. [PDF]
PLoS ONE, 2016 Cardiac hypertrophy is a key pathological process of many cardiac diseases. However, early detection of cardiac hypertrophy is difficult by the currently used non-invasive method and new approaches are in urgent need for efficient diagnosis of cardiac ...
Xiangbo An +7 more
doaj +1 more source
TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Pathological cardiac hypertrophy is a major cause of heart failure morbidity. The complex mechanism of intermolecular interactions underlying the pathogenesis of cardiac hypertrophy has led to a lack of development and application of ...
Jian Li +7 more
doaj +1 more source
FOXO3a-dependent PARKIN negatively regulates cardiac hypertrophy by restoring mitophagy
Cell & Bioscience, 2022 Background Sustained cardiac hypertrophy often develops maladaptive myocardial remodeling, and eventually progresses to heart failure and sudden death.
Teng Sun +9 more
doaj +1 more source
Cell Death Discovery, 2022 s Pathological cardiac hypertrophy is a key contributor in heart failure (HF). Long non-coding RNAs (lncRNAs) and N6-methyladenosine (m6A) modification play a vital role in cardiac hypertrophy respectively.
Yiqing Yang +5 more
doaj +1 more source
Differential and conditional activation of PKC-isoforms dictates cardiac adaptation during physiological to pathological hypertrophy. [PDF]
PLoS ONE, 2014 A cardiac hypertrophy is defined as an increase in heart mass which may either be beneficial (physiological hypertrophy) or detrimental (pathological hypertrophy).
Shaon Naskar +6 more
doaj +1 more source